The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Are we one of these two companies?
LCM's investment related to a portfolio of two separate construction related disputes. One dispute was heard in the SIAC (Singapore International Arbitration Centre) and the other determined via an arbitration seated in Hong Kong SAR. LCM provided funding to the claimants in both proceedings, which recently received awards in their favour. The subject matter, findings and funding terms remain subject to confidentiality.
Partial payment has been received with respect to one of the two portfolio investments, with the final return expected following the Tribunals' final determinations in relation to interest and costs. The overall financial performance of these investments is expected to be commensurate with LCM's past performance metrics. These Tribunal determinations are anticipated before the end of the current financial year, at which point an announcement with details about our final return will be made
On the RICHTER SCALE ⚖️ of breakthroughs, in the world of Pharmacy companies and laboratories around the world, Is this very high ? Will it be in most journals and talked about ? Will it be want by by the bigger fish ? Is there more potential 🤔
Just reading the last few posts, so so much upside, and I'm sure big boys want this in their portfolio...again as someone mentioned, this went up at nice steady rise all day, I'm sure the angle, could run for a good period of time and maybe a nice sharp upward curve.
If I go by memory, Market would push up PAT mcap 5% if they belive we don't have much chance of claiming any monies.
And about 20% if a good chance of winning our claim.
So say pessimistic £1 billion 5% = £50 million x5 mcap
Or optimistic £1 billion 20% = £200 million x20 mcap
(Could be half that or double 500million to 2 billion.)